We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

LumiraDx’s Broad Menu of Lab Comparable Results on Single, Portable Diagnostic Platform Promises to Transform Community Care

By LabMedica International staff writers
Posted on 13 Nov 2021
Print article
Image: LumiraDx Platform and Test Strip (Photo courtesy of LumiraDx)
Image: LumiraDx Platform and Test Strip (Photo courtesy of LumiraDx)

LumiraDx (London, UK) is offering a broad menu of lab comparable results on the LumiraDx Platform, its next generation point of care diagnostic system, that aims to transform community care.

The LumiraDx Platform combines a small, portable instrument, advanced low cost test strip and seamless secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays across a number of parameters, in a portable, easy-to-use point of care solution. The platform is designed to go wherever the patient is, whether this is in a hospital, medical office, pharmacy, or in other non-traditional settings such as schools or airports. Easy and intuitive to use, it requires only basic training and is designed to be affordable and accessible at the point of care. The company has a pipeline of more than 30 assays, initially focused on some of the most common conditions being diagnosed or managed with POC testing such as coagulation disorders, infectious diseases, cardiovascular and diabetes.

LumiraDx has developed SARS-CoV-2 antigen and antibody tests that provide lab comparable results for COVID-19 testing in minutes on a single platform. The LumiraDx SARS-CoV-2 Ag Test on the LumiraDx platform enables physicians to verify infection quickly, begin proper treatment and to initiate isolation precautions helping prevent further spread of infection. Similarly, the LumiraDx SARS-CoV-2 Ab Test is designed to be used in community care settings to identify individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The company also offers the SARS-CoV-2 Ag Surveillance Test for environments such as schools and workplaces that allows simultaneous testing of up to five samples on its platform with cost per sample as low as USD 4. With digital results in less than 12 minutes from sample application and a comprehensive connectivity solution, it is designed to measure population health metrics in real-time to help prevent the spread of infection using the LumiraDx affordable, easy-to-use, onsite testing platform.

The LumiraDx Platform menu also includes point of care tests for INR and D-Dimer with high levels of accuracy comparable to central lab-based tests. The LumiraDx INR Test measures prothrombin time reported as International Normalized Ratio (INR) from a single, direct fingerstick blood sample - all in less than 90 seconds. The LumiraDx D-Dimer Test is an easy to use fluorescence immunoassay designed to rapidly quantify D-Dimer levels in human whole blood and plasma at the point of care. It is the first quantitative micro-fluidic immunoassay of its kind, providing a precise and accurate D-Dimer result from a single direct fingerstick blood sample, in only six minutes. All point of care tests on the LumiraDx Platform menu have achieved CE Mark and are commercially available in Europe.

Related Links:
LumiraDx 

New
Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
New
Laboratory Automation System
UniVerse
New
Semi-Automated Coagulation Analyzer
Thrombo Fast+
New
Silver Supplier
Automated RPR Syphilis Test
Automated RPR Test Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more

Immunology

view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more

Microbiology

view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more

Pathology

view channel
Illustration

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.